CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types.
Zheng X, Jiang K, Xiao W, Zeng D, Peng W, Bai J, Chen X, Li P, Zhang L, Zheng X, Miao Q, Wang H, Wu S, Xu Y, Xu H, Li C, Li L, Gao X, Zheng S, Li J, Wang D, Zhou Z, Xia X, Yang S, Li Y, Cui Z, Zhang Q, Chen L, Lin X, Lin G.
Zheng X, et al. Among authors: li c, li y, li j, li l, li p.
Front Immunol. 2022 Nov 9;13:974265. doi: 10.3389/fimmu.2022.974265. eCollection 2022.
Front Immunol. 2022.
PMID: 36439099
Free PMC article.